Sylentis said this week that it has received clearance from Spanish regulators to begin a second phase I/II trial of its siRNA-based ocular hypertension drug SYL040012.
The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers (GSN 7/8/2010).
The new trial will enroll patients with elevated intraocular pressure. Sylentis aims to develop SYL040012 as a glaucoma treatment.